Navigation Links
Hospitalization Rates for Coronary Artery Disease Decline in the,U.S.

EVANSTON, Ill., March 20, 2007 /PRNewswire/ -- Treatment of coronary artery disease (CAD) appears to be shifting away from the inpatient setting, according to a study published today in The American Journal of Cardiology.

U.S. hospitalization rates for heart attacks (acute myocardial infarctions) declined 10.6 percent from 2002 to 2005, possibly due to broader use of preventive treatments such as statin drugs and aspirin, as well as declines in risk factors like smoking.

The study is a collaboration between researchers from the University of Michigan Medical School and Solucient, part of Thomson Healthcare, a leading provider of information and solutions to improve the cost and quality of healthcare.

"Although there was an expectation that the aging U.S. population would cause an increased need for inpatient care of patients with cardiovascular disease, the reality is that changes in treatment may be causing a shift to the outpatient setting," said Janet Young, M.D., a senior scientist at Solucient. "This trend has important implications for hospitals and health systems and their allocation of resources."

    Researchers found that:

     - Hospitalizations for acute myocardial infarction (AMI) decreased

       steadily from 661,000 in 2002 to 591,000 in 2005 -- a decline from 309

       to 266 per 100,000 persons. This was driven by a decrease in the more

       severe transmural form of AMI from 118 to 87 per 100,000.

     - Hospitalization rates for coronary revascularization declined from 382

       to 358 per 100,000 persons from 2002 to 2005 -- largely due to a

       decrease in coronary artery bypass surgeries from 258,000 to 209,000

       per year.

     - During this period, inpatient use of less-invasive revascularization

       treatments known as percutaneous coronary interventions -- including

       the use of balloon angioplasty and stents administered via cardiac

       catheterization -- increased from 5
'"/>




Page: 1 2 3

Related medicine technology :

1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
3. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
7. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
8. New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
9. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
10. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
11. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hospitalization Rates for Coronary Artery Disease Decline the
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
(Date:8/29/2014)... Pursuing its deepest desires to help build ... stunning new design that promises to redefine the global ... surrogacy platform has witnessed a 42 percent increase in ... month, the FindSurrogateMother.com community is formed by hopeful parents ... — the precious gift of life. , Whether intended ...
(Date:8/29/2014)... News) -- If you have bunions, taking care of them ... expert says. A bunion is a bump that forms ... tissue moves out of place and extends beyond the normal ... pain and may require surgery to correct, said Brent Rosenthal, ... Freehold, N.J. To prevent bunions, avoid wearing shoes with ...
(Date:8/29/2014)... NEW YORK August 29, 2014 - Despite US ... obesity, there are many barriers, several of which may ... study by researchers at NYU Langone Medical Center published ... General Internal Medicine ( JGIM ). , David ... Department of Internal Medicine at NYU Langone, and colleagues ...
(Date:8/29/2014)... AURORA, Colo. (Sept. 2, 2014) A team of ... has reported the breakthrough discovery of a process to ... patients. These findings could have implications that extend beyond ... and autoimmune diseases., In an article published ... the Charles C. Gates Center for Regenerative Medicine and ...
(Date:8/29/2014)... 29, 2014 Today, NBC’s “The ... who profiled a handful of safe, back to ... Research. This year, many schools will include earphones ... innovator of hearing wellness solutions, offers the best ... Earphones, offered in yellow, pink and black, sound ...
Breaking Medicine News(10 mins):Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2
... N.Y., Oct. 8 Moog Inc. (NYSE:,MOG.A and ... are adopting,the Moog brand name. The organizations and ... to an expanded product portfolio within a,single, well-established ... continue to be associated with the,products, this event ...
... by Leading Architectural Firms, LISBON, Portugal ... weeks after,awarding two Johns Hopkins University scientists ... for their research in combating blindness, the,Antonio ... medical,research with the groundbreaking of its 300,000-square-foot ...
... safe substitutes for authentic,FDA approved injectables, NEW ... cosmetic injectables are a threat to your looks,and ... Safety. "The,growing acceptance of cosmetic injections for their ... cautions," says Coalition,leader, plastic surgeon Jeffrey Kenkel, MD ...
... Hodgkin lymphoma, a common form of cancer of the ... blood cells (B cells), but have lost a considerable ... phenotype and the characteristics of Hodgkin lymphoma cells are ... Delbrck Center for Molecular Medicine, MDC, Berlin-Buch and Charit ...
... of Defense has awarded The University of Texas Health ... conduct a multi-center clinical trial that could lead to ... both soldiers and civilians -- who require massive blood ... Sciences (CCTS) is contracting with the U.S. Army Institute ...
... closer to understanding the spread of deadly diseases such ... bacteria respond to stress. , The research, published in ... Science , details how a huge molecule called a ... , Scientists from the University of Newcastle in ...
Cached Medicine News:Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 2Health News:World Renowned Champalimaud Foundation Extends its Mission with Groundbreaking for Cutting-Edge Research Center 3Health News:Illegal Botox Scammers a Public Threat 2Health News:Illegal Botox Scammers a Public Threat 3Health News:Illegal Botox Scammers a Public Threat 4Health News:Illegal Botox Scammers a Public Threat 5Health News:Hodgkin lymphoma -- new characteristics discovered 2Health News:Hodgkin lymphoma -- new characteristics discovered 3Health News:UT researchers to study massive transfusion at major trauma centers 2Health News:Protection for stressed-out bacteria identified 2
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
... anesthesia solution for the MRI environment , ... ,The Narkomed MRI-2 is the only ... monitor, designed and engineered to perform, without distance ... environments of up to 3.0 Tesla. This feature ...
... Narkomed GS provides high quality ventilation ... The proven technologies of the AV2+ ... the Narkomed GS user-friendly and intuitive. ... quality Narkomed GS is the perfect ...
... facilities where space is a premium Fabius ... delivery technologies with an ergonomic and compact ... of the Draeger Infinity patient monitoring range ... environment that is a sound investment into ...
Medicine Products: